Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy
- Data from Ongoing Phase 1/2 Study Presented at the 2017 European Society for Medical Oncology… Read more
Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory
Clinical Data from Ongoing Phase 1/2 Trial of IMO-2125 in anti-PD-1 Refractory Melanoma to be… Read more
Idera to Host Investor Conference Call on Monday, September 11, 2017 at 9:00 A.M. E.T.
CAMBRIDGE, Mass. and EXTON, Pa. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more